AI and blood tests aim to catch pancreatic cancer earlier

NCT ID NCT07324096

Recruiting now Knowledge-focused Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new screening program for people aged 50 to 85 who have recently developed diabetes and are at high risk for pancreatic cancer. Participants will receive repeated AI-enhanced CT scans and blood draws over time to see if these tools can spot cancer earlier than usual. The goal is to find out if this approach is practical and acceptable for high-risk individuals, potentially leading to better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this screening program could enable earlier detection of pancreatic cancer, potentially improving survival rates for high-risk individuals.
What could go wrong: This is a small feasibility study (100 participants) focused on whether the program is practical, not on proving it saves lives. The approach may not detect cancer early enough or may lead to false alarms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Mayo Clinic in Rochester
RECRUITING

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.